GLP-1 weight loss medication cost in 2026 — the honest answer:
Branded GLP-1 medications for weight loss are not affordably available on a cash-pay basis for most patients. Wegovy (semaglutide) retails at $1,350–$1,640/month without insurance; Zepbound (tirzepatide) retails at ~$1,271/month (GoodRx, April 2026; GoodRx, April 2026). GoodRx savings programs reduce Wegovy to $199–$349/month and Zepbound to ~$995/month — still $2,400–$12,000/year. Most insurers, including Aetna, cover GLP-1s only with prior authorization after documented BMI ≥35 and 6+ months of lifestyle intervention. Compounded semaglutide, previously available via 503B outsourcing facilities during the shortage, is now being phased out following FDA's April 2026 proposal to exclude these drugs from the 503B bulk list (FDA, April 2026). The $49 TeleDirectMD visit helps you navigate insurance PA, assess metformin as a lower-cost alternative, and determine whether bariatric referral is appropriate.
How much does glp-1 weight loss cost in 2026?
GLP-1 Weight Loss Drug Cost: What Wegovy, Zepbound, and Telehealth Actually Cost in 2026
The $49 TeleDirectMD visit evaluates your weight management options, navigates GLP-1 insurance prior authorization, and offers ADA-guideline-aligned alternatives — because branded GLP-1s are not affordable for most cash-pay patients at $1,000–$1,600/month.
GLP-1 receptor agonists (Wegovy, Zepbound) have transformed obesity medicine — and generated enormous confusion about what they actually cost. The answer: retail pricing is $1,271–$1,640/month, most insurers heavily restrict access, compounded alternatives are being phased out by FDA regulation, and honest guidance requires a clear-eyed look at all four pathways — insurance coverage, manufacturer savings programs, cash-pay reality, and evidence-based non-GLP-1 alternatives. We break it all down with verified 2026 pricing and guideline-based clinical context.
- Clear, honest GLP-1 cost navigation — $49 vs. confusion navigating $1,300+/month medications
- PA documentation support: Aetna requires BMI ≥35 + 6-month lifestyle program — we document it
- Metformin as ADA-endorsed first-line: as low as $5.75/month via GoodRx vs. $1,350/month for Wegovy
- Compounded semaglutide landscape explained: FDA 503B proposal means most compounders are exiting
- No false promises about affordable cash-pay GLP-1s — they don't exist at scale
- Bariatric surgery referral for appropriate candidates: more durable outcomes than GLP-1 for BMI ≥40
Cost comparison last updated 2026-05-20. Reviewed by Parth Bhavsar, MD — Board-Certified Family Medicine · NPI 1104323203 · LegitScript Certified · HIPAA-Compliant.
Weight Management Visit at TeleDirectMD: $49
- Comprehensive weight management evaluation with a board-certified MD
- GLP-1 prior authorization navigation and documentation support
- ADA 2026 guideline-based pathway: lifestyle + metformin + GLP-1/SGLT-2 when indicated
- Metformin prescription if appropriate (as low as $5.75/month)
- Bariatric referral for BMI ≥40 or ≥35 with comorbidities when appropriate
- HSA/FSA accepted — 41 states, same-day availability
5.0 ★ from 125 verified patient reviews across Google, Zocdoc, WebMD, and Healthgrades.
GLP-1 Weight Loss Treatment Cost by Care Setting (2026, Cash-Pay Total)
Visit cost only for telehealth rows; GLP-1 medication cost listed separately due to extreme price range. Medication column reflects monthly drug cost without insurance.
| Setting | Typical Cost (Cash-Pay) | What's Included |
|---|---|---|
| TeleDirectMD (online evaluation) | $49 visit | Obesity evaluation, PA navigation, lifestyle counseling, metformin Rx if appropriate — GLP-1 drug cost separate · TeleDirectMD |
| Wegovy (semaglutide) — cash-pay | $1,350–$1,640/month | Retail list price; GoodRx savings program: $199–$349/month (introductory/ongoing) · GoodRx, April 2026 |
| Zepbound (tirzepatide) — cash-pay | ~$1,271/month | Retail list price; GoodRx: ~$995/month with coupon · GoodRx, April 2026 |
| Metformin (ADA first-line alternative) | $5.75–$9/month | Generic 500mg–1000mg, 60–180 tablets — first-line ADA 2026 therapy for T2DM + weight management · GoodRx, April 2026 |
| Primary care weight management (cash-pay) | $110–$265/visit | In-person consultation; GLP-1 Rx requires PA regardless of visit type · Mira Health, 2025 |
| Emergency room (obesity complication) | $1,500–$5,000+ | Not applicable for routine weight management — listed as context for complications · BetterCare, 2025 |
Prices reflect 2025–2026 cash-pay/uninsured figures. Actual costs vary by geography, facility, and services rendered. See the References section for full source citations.
The Honest GLP-1 Cost Guide: Insurance Reality, FDA Compounding Changes, and What Actually Works
The insurance picture: prior authorization is nearly universal. Most commercial insurers, including Aetna, cover GLP-1 medications for weight management only with significant prior authorization requirements. According to Aetna's 2024 clinical policy, approval requires: (1) BMI ≥35 kg/m²; (2) documented participation in a comprehensive behavioral weight management program for at least 6 months prior to drug therapy; and (3) condition-specific criteria for each agent. Step therapy is common — insurers often require documented failure of lifestyle + metformin before approving a GLP-1. The telehealth visit's most practical value for GLP-1 access is generating the documentation Aetna and other payers require. Penn Medicine's 2026 study found telemedicine averaged $96 vs. $509 for in-person visits (Penn Medicine, 2026) — meaning navigating the PA process via telehealth is both faster and cheaper than an endocrinology or weight management specialist visit.
The compounded GLP-1 landscape — what's changed in 2026. During the 2022–2025 semaglutide shortage, 503B outsourcing facilities legally compounded semaglutide and tirzepatide at significantly lower cost. FDA declared the semaglutide shortage resolved on February 21, 2025 and the tirzepatide shortage resolved in 2025. On April 30, 2026, the FDA proposed to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulk drug substances list — finding no clinical need for outsourcing facilities to compound these drugs from bulk (FDA Press Announcement, April 30, 2026). This proposal, with a public comment period closing June 29, 2026, signals the end of large-scale 503B compounded GLP-1 supply. Section 503A patient-specific compounding (for documented clinical need — e.g., patient allergy to excipients, non-standard dosing requirement) may continue in narrow circumstances, but the broad availability of compounded "budget" GLP-1s from outsourcing facilities is ending. Patients who were relying on compounded semaglutide should ask their provider about transitioning to FDA-approved branded products and insurance PA, or consider alternative weight management strategies.
Evidence-based alternatives the ADA actually endorses. Per the ADA 2026 Standards of Care, the evidence-based approach to type 2 diabetes with obesity is layered: lifestyle optimization first (Mediterranean diet, structured exercise, sleep), then metformin (as low as $5.75/month via GoodRx, the cheapest and most studied oral agent), then early addition of SGLT-2 inhibitors or GLP-1 receptor agonists when cardiovascular, renal, or weight risk warrants it. Metformin produces modest but real weight loss (2–3 kg average) and costs $5.75–$9/month vs. $1,271–$1,640/month for GLP-1s. For patients with BMI ≥40, or BMI ≥35 with obesity-related comorbidities who have not responded to medical management, the ADA 2026 Standards and ACC/AHA 2024 guidelines support bariatric surgery referral as offering the most durable long-term weight loss and metabolic benefit — and bariatric surgery may ultimately cost less than 5+ years of GLP-1 therapy at $12,000–$18,000/year.
Why TeleDirectMD: A Real Doctor, Not an Algorithm
When you visit TeleDirectMD, you see Dr. Parth Bhavsar, MD — a board-certified Family Medicine physician licensed in 41 states. Not a panel of rotating providers, not a physician assistant, not a chatbot.
- Board-certified Family Medicine — University of Mississippi Medical Center
- NPI 1104323203 — verifiable in the NPPES NPI Registry
- 5.0 ★ across 125 verified reviews (Google, Zocdoc, WebMD, Healthgrades)
- LegitScript-certified telehealth practice
- HIPAA-compliant platform — encrypted video, secure records, no data resale
- In-network with Aetna, BCBS, and UnitedHealthcare in select states
Patient Reviews — 5.0 / 5 Across 125 Verified Reviews
Verified patient ratings of Dr. Parth Bhavsar, MD aggregated from independent third-party review platforms:
Available in 41 States
The flat $49 rate applies in every state where Dr. Bhavsar is licensed. Select your state:
Conditions Commonly Treated at the $49 Visit
The same flat $49 visit covers any of these adult conditions:
Insurance Accepted (Select States)
TeleDirectMD is in-network with three major insurers. Your standard telehealth copay applies in place of the $49 self-pay fee.
Don't see your plan? View all insurance options or book the flat $49 self-pay visit.
$49 Flat. HSA / FSA Accepted.
- Board-certified MD video consultation
- E-prescription to any US pharmacy
- HSA / FSA-eligible
- No facility fees, no surprise billing
- Receipt suitable for travel-insurance reimbursement
Cash-Pay Cost vs. Other Settings
Sources: Mira Health 2025; GoodRx 2024; CVS MinuteClinic 2024.
How a $49 TeleDirectMD Visit Works
Book online
Pick a same-day or next-available appointment at teledirectmd.com/book-online. Pay $49 at checkout (or use HSA/FSA, or apply your in-network insurance).
Connect by video
At your appointment time, click the link to start a secure video visit with Dr. Bhavsar. No app download. Most visits take 10–15 minutes.
Get treated, fill the script
Receive a diagnosis, a written visit summary, and an e-prescription routed to your pharmacy of choice — usually within 30 minutes of the visit.
Who Benefits Most From a Telehealth GLP-1 / Weight Management Visit
Patients who want GLP-1s and have commercial insurance
The $49 telehealth visit generates the PA documentation Aetna, BCBS, and UHC require — BMI verification, prior lifestyle program evidence, and step therapy documentation.
Patients currently on compounded semaglutide
FDA's April 2026 proposal means outsourcing facility compounders are winding down. A telehealth visit helps you navigate the transition to branded products or alternatives.
Patients with T2DM or prediabetes + weight concerns
ADA 2026 guidelines support metformin + lifestyle as first-line — effective, cheap, and far more accessible than GLP-1 PA approval. A $49 visit can start you on the right protocol.
High-BMI patients considering bariatric surgery
For BMI ≥40 or ≥35 with comorbidities, a telehealth visit provides a structured evaluation and bariatric referral — often the most cost-effective long-term path.
When GLP-1 Weight Management Belongs in Telehealth vs. In-Person
Good fit for telehealth
- Initial obesity evaluation and PA documentation for GLP-1 insurance coverage
- Metformin initiation for T2DM + weight management (ADA first-line)
- Counseling on evidence-based lifestyle intervention (required before GLP-1 PA approval)
- Transition from compounded semaglutide to FDA-approved branded product
- Monitoring existing GLP-1 therapy — GI side effects, dose titration check-in
- Bariatric surgery referral evaluation for BMI ≥40 or ≥35 with comorbidities
Better seen in person
- Severe GLP-1 side effects: pancreatitis symptoms, severe vomiting, severe abdominal pain — in-person or ER
- Eating disorders or history of thyroid C-cell tumors — specialist evaluation required
- Injectable GLP-1 initiation without in-person cardiovascular risk stratification for high-risk patients
- Bariatric surgery itself — in-person surgical evaluation, program, and procedure required
- Children and adolescents with obesity — pediatric endocrinology preferred
- Patients with uncontrolled psychiatric conditions affecting weight — in-person team-based care
GLP-1 / Weight Loss: Telehealth, Specialist, or Surgery?
BMI ≥35, commercial insurance — want GLP-1 coverage?
Book a $49 telehealth visit. We document your BMI, lifestyle history, and prior therapy for the PA submission Aetna and other payers require. The evaluation is the first step — not the drug.
Cash-pay only — expecting affordable GLP-1 access?
Honest answer: cash-pay branded GLP-1s cost $995–$1,640/month (GoodRx, April 2026) — not feasible for most patients. Compounded alternatives are being phased out under FDA's April 2026 503B proposal. A telehealth visit helps set realistic expectations and explore metformin, lifestyle, or insurance pathways.
T2DM or prediabetes with weight concerns — uninsured?
Metformin is $5.75–$9/month via GoodRx and is ADA 2026 first-line therapy. A $49 telehealth visit starts the right evidence-based protocol without the GLP-1 cost barrier.
BMI ≥40 or severe comorbidities — GLP-1s not working or not affordable?
A telehealth visit provides a structured evaluation and generates a bariatric surgery referral if appropriate. Surgery produces more durable outcomes than GLP-1 therapy for the highest-BMI patients and may cost less than 5 years of medication.
Weight Management Medication Costs (GoodRx Cash Price, April 2026)
Monthly supply. GLP-1 branded prices reflect retail list; GoodRx savings program prices in parentheses. Insurance coverage varies — PA required for GLP-1s at most plans.
| Medication | Cash-Pay Price (with GoodRx) | Source |
|---|---|---|
| Metformin 500mg–1000mg — ADA 2026 first-line, T2DM + weight management | $5.75–$9/month (180 tablets) | GoodRx |
| Wegovy (semaglutide) — FDA-approved weight loss, requires PA | $1,350–$1,640/month retail ($199–$349 GoodRx savings program) | GoodRx |
| Zepbound (tirzepatide) — FDA-approved weight loss, requires PA | ~$1,271/month retail (~$995 GoodRx coupon) | GoodRx |
| Compounded semaglutide — 503B outsourcing winding down per FDA April 2026 proposal | Variable; most outsourcing facilities exiting market | GoodRx |
While You Navigate GLP-1 Insurance or Explore Alternatives
- Structured dietary changes (Mediterranean diet, caloric deficit of 500–750 kcal/day) produce 5–10% weight loss in 6 months — required evidence for most GLP-1 PA approvals.
- If starting metformin: take with food to reduce GI side effects; extended-release formulation available and better tolerated for some patients.
- Maintain a 6-month record of lifestyle program participation — Aetna and most major payers require documented behavioral program enrollment for GLP-1 PA.
- GLP-1 GI side effects (nausea, constipation) are common early; slow titration, smaller meals, and avoiding high-fat foods reduces severity.
- If you were on compounded semaglutide: do not abruptly stop without transitioning to a plan — contact your provider for guidance given the FDA compounding landscape changes.
- Sleep optimization (7–9 hours/night) independently reduces ghrelin and supports weight management — often overlooked.
When NOT to Pursue GLP-1 Therapy Without In-Person Evaluation
- Personal or family history of medullary thyroid carcinoma or MEN2 syndrome — GLP-1s are contraindicated.
- History of pancreatitis — GLP-1s should be used with caution; in-person gastroenterology clearance recommended.
- Active eating disorder — weight loss medications require specialist supervision.
- Pregnancy or planning pregnancy — GLP-1s are not indicated and potential fetal effects are understudied.
- Severe nausea, vomiting, or inability to eat on GLP-1 — needs in-person evaluation for dehydration and medication adjustment.
- Expecting affordable cash-pay GLP-1 access — compounded options are ending per FDA April 2026 proposal; branded prices are $995–$1,640/month.
Frequently Asked Questions
How much do Wegovy and Zepbound cost without insurance in 2026?
Wegovy (semaglutide) has a retail list price of approximately $1,350–$1,640 per month without insurance (GoodRx, April 2026). Zepbound (tirzepatide) averages ~$1,271/month retail. GoodRx savings programs can reduce Wegovy to $199–$349/month and Zepbound to ~$995/month — still $2,400–$12,000 annually. These are not affordably accessible for most uninsured patients on an ongoing basis.
Does insurance cover Wegovy or Zepbound?
Some commercial plans do, but coverage requires prior authorization. Aetna's 2024 clinical policy requires BMI ≥35, documented participation in a comprehensive behavioral weight management program for 6+ months prior to GLP-1 therapy, and condition-specific criteria. Medicare Part D currently does not cover weight loss medications (though legislation is pending). Employer-sponsored plans increasingly exclude GLP-1s for weight management due to cost.
Is compounded semaglutide still available in 2026?
Access is ending. On April 30, 2026, the FDA proposed to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulk drug substances list, finding no clinical need for outsourcing facilities to compound these drugs (FDA, April 2026). 503B outsourcing facilities — which supplied most "compounded GLP-1" products — cannot continue once this proposal is finalized. Narrow 503A patient-specific compounding may continue for documented individual clinical needs, but the broad affordable compounded market is shutting down.
What does the TeleDirectMD $49 visit actually do for GLP-1 access?
The visit generates the clinical documentation most insurers require for GLP-1 prior authorization: BMI documentation, comorbidity assessment, prior lifestyle intervention evidence, and the prescriber attestation. It also evaluates whether metformin or an SGLT-2 inhibitor is a better-value alternative, discusses realistic cash-pay costs, and provides a bariatric referral pathway for BMI ≥40 when appropriate.
What is a cheaper evidence-based alternative to GLP-1 medications?
Metformin is ADA 2026's first-line recommendation and costs as little as $5.75/month via GoodRx — compared to $1,271–$1,640/month for GLP-1s. It produces modest but clinically meaningful weight loss (2–3 kg average), reduces cardiovascular and diabetes risk, and is extremely well tolerated. Structured lifestyle intervention (500–750 kcal/day deficit, 150+ min/week of aerobic exercise) adds further benefit. For BMI ≥40, bariatric surgery referral may be more cost-effective than years of GLP-1 therapy.
How does Wegovy's GoodRx savings program work?
Novo Nordisk's savings programs (accessible via GoodRx) offer introductory pricing of $199/month for the first two Wegovy injection fills, then $349/month for ongoing maintenance doses. Pill forms of Wegovy start at $149/month for certain doses. These are manufacturer savings programs, not insurance — they apply to out-of-pocket payers who have no insurance covering Wegovy. They require eligibility verification and have terms that vary by dose.
Can I get a GLP-1 prescription via telehealth?
Yes — a telehealth MD can evaluate your eligibility and write the prescription. The bottleneck is not the prescription but the insurance prior authorization, which is required by virtually all plans that cover these medications. A TeleDirectMD provider helps you build the PA documentation case. For cash-pay patients, the honest discussion is that branded GLP-1s at $995–$1,640/month are not sustainably affordable for most households.
Should I consider bariatric surgery instead of GLP-1 medications?
For BMI ≥40 or ≥35 with obesity-related comorbidities (T2DM, hypertension, sleep apnea), the ADA 2026 Standards of Care and ACC/AHA guidelines support bariatric surgery as offering greater and more durable weight loss than pharmacotherapy alone. Many insurance plans cover bariatric surgery with PA. Given that branded GLP-1s cost $12,000–$18,000/year indefinitely, bariatric surgery may ultimately be more cost-effective for appropriate patients. A TeleDirectMD evaluation can help determine whether a surgical referral is appropriate.
Related Cost Guides
Compare TeleDirectMD to Other Telehealth Platforms
Side-by-side comparisons with verified 2026 cash-pay pricing and inline source citations on every claim:
Stop guessing. Book a $49 visit and know your cost upfront.
Same-day. No insurance required. HSA/FSA accepted. 41 states. Last verified 2026-05-20.
References
- GoodRx — Wegovy (semaglutide) pricing and savings (April 2026)
- GoodRx — Zepbound (tirzepatide) pricing (April 2026)
- GoodRx — Metformin pricing (April 2026)
- FDA — Proposes to exclude semaglutide, tirzepatide, liraglutide from 503B bulks list (April 30, 2026)
- FDA — GLP-1 compounding policy clarification (April 2026)
- Aetna — GLP-1 benefit coverage and PA policy
- ADA — Standards of Care in Diabetes 2026
- Penn Medicine — Telemedicine vs. in-person costs, JAMA Network Open (2026)
- BetterCare — Urgent care and ER cost (2025)
- Mira Health — Primary care cost without insurance (2025)
Medical Disclaimer & Pricing Caveats
Cost figures on this page reflect 2025–2026 cash-pay/uninsured averages or ranges from public sources (KFF, Mira Health, GoodRx, Penn Medicine, CVS MinuteClinic, BetterCare). Actual costs vary by geography, facility, and services rendered. This page is informational only and does not constitute medical advice or a guarantee of pricing. TeleDirectMD provides telehealth services for non-emergency conditions in adults 18+ physically located in one of our 41 licensed states at the time of the visit. We do not prescribe controlled substances. If you are experiencing a medical emergency, call 911 immediately.